Recent Advances in the Discovery and Preclinical Testing of Novel Compounds for the Prevention and/or Treatment of Alcohol Use Disorders

Daryl L. Davies, Marco Bortolato, Deborah (Deb) Finn, Marcia J. Ramaker, Segev Barak, Dorit Ron, Jing Liang, Richard W. Olsen

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Alcohol abuse and dependence have a staggering socioeconomic impact, yet current therapeutic strategies are largely inadequate to treat these disorders. Thus, the development of new strategies that can effectively prevent alcohol use disorders (AUDs) is of paramount importance. Currently approved medications attempt to deter alcohol intake by blocking ethanol metabolism or by targeting the neurochemical systems downstream of the cascades leading to craving and dependence. Unfortunately, these medications have provided only limited success as indicated by the continued high rates of alcohol abuse and alcoholism. The lack of currently available effective treatment strategies is highlighted by the urgent call by the NIAAA to find new and paradigm-changing therapeutics to either prevent or treat alcohol-related problems. This mini-review highlights recent findings from 4 laboratories with a focus on compounds that have the potential to be novel therapeutic agents that can be developed for the prevention and/or treatment of AUDs.

Original languageEnglish (US)
Pages (from-to)8-15
Number of pages8
JournalAlcoholism: Clinical and Experimental Research
Volume37
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Alcoholism
Alcohols
Testing
National Institute on Alcohol Abuse and Alcoholism (U.S.)
Ethanol
Therapeutics
Metabolism

Keywords

  • Dihydromyricetin
  • GABA receptors
  • Ganaxolone
  • Glial cell line-derived neurotrophic factor
  • Ivermectin
  • Purinergic receptors

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychiatry and Mental health
  • Toxicology

Cite this

Recent Advances in the Discovery and Preclinical Testing of Novel Compounds for the Prevention and/or Treatment of Alcohol Use Disorders. / Davies, Daryl L.; Bortolato, Marco; Finn, Deborah (Deb); Ramaker, Marcia J.; Barak, Segev; Ron, Dorit; Liang, Jing; Olsen, Richard W.

In: Alcoholism: Clinical and Experimental Research, Vol. 37, No. 1, 01.2013, p. 8-15.

Research output: Contribution to journalArticle

Davies, Daryl L. ; Bortolato, Marco ; Finn, Deborah (Deb) ; Ramaker, Marcia J. ; Barak, Segev ; Ron, Dorit ; Liang, Jing ; Olsen, Richard W. / Recent Advances in the Discovery and Preclinical Testing of Novel Compounds for the Prevention and/or Treatment of Alcohol Use Disorders. In: Alcoholism: Clinical and Experimental Research. 2013 ; Vol. 37, No. 1. pp. 8-15.
@article{5abb16dfc2b04d6f80e9d1a8c1a30e80,
title = "Recent Advances in the Discovery and Preclinical Testing of Novel Compounds for the Prevention and/or Treatment of Alcohol Use Disorders",
abstract = "Alcohol abuse and dependence have a staggering socioeconomic impact, yet current therapeutic strategies are largely inadequate to treat these disorders. Thus, the development of new strategies that can effectively prevent alcohol use disorders (AUDs) is of paramount importance. Currently approved medications attempt to deter alcohol intake by blocking ethanol metabolism or by targeting the neurochemical systems downstream of the cascades leading to craving and dependence. Unfortunately, these medications have provided only limited success as indicated by the continued high rates of alcohol abuse and alcoholism. The lack of currently available effective treatment strategies is highlighted by the urgent call by the NIAAA to find new and paradigm-changing therapeutics to either prevent or treat alcohol-related problems. This mini-review highlights recent findings from 4 laboratories with a focus on compounds that have the potential to be novel therapeutic agents that can be developed for the prevention and/or treatment of AUDs.",
keywords = "Dihydromyricetin, GABA receptors, Ganaxolone, Glial cell line-derived neurotrophic factor, Ivermectin, Purinergic receptors",
author = "Davies, {Daryl L.} and Marco Bortolato and Finn, {Deborah (Deb)} and Ramaker, {Marcia J.} and Segev Barak and Dorit Ron and Jing Liang and Olsen, {Richard W.}",
year = "2013",
month = "1",
doi = "10.1111/j.1530-0277.2012.01846.x",
language = "English (US)",
volume = "37",
pages = "8--15",
journal = "Alcoholism: Clinical and Experimental Research",
issn = "0145-6008",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Recent Advances in the Discovery and Preclinical Testing of Novel Compounds for the Prevention and/or Treatment of Alcohol Use Disorders

AU - Davies, Daryl L.

AU - Bortolato, Marco

AU - Finn, Deborah (Deb)

AU - Ramaker, Marcia J.

AU - Barak, Segev

AU - Ron, Dorit

AU - Liang, Jing

AU - Olsen, Richard W.

PY - 2013/1

Y1 - 2013/1

N2 - Alcohol abuse and dependence have a staggering socioeconomic impact, yet current therapeutic strategies are largely inadequate to treat these disorders. Thus, the development of new strategies that can effectively prevent alcohol use disorders (AUDs) is of paramount importance. Currently approved medications attempt to deter alcohol intake by blocking ethanol metabolism or by targeting the neurochemical systems downstream of the cascades leading to craving and dependence. Unfortunately, these medications have provided only limited success as indicated by the continued high rates of alcohol abuse and alcoholism. The lack of currently available effective treatment strategies is highlighted by the urgent call by the NIAAA to find new and paradigm-changing therapeutics to either prevent or treat alcohol-related problems. This mini-review highlights recent findings from 4 laboratories with a focus on compounds that have the potential to be novel therapeutic agents that can be developed for the prevention and/or treatment of AUDs.

AB - Alcohol abuse and dependence have a staggering socioeconomic impact, yet current therapeutic strategies are largely inadequate to treat these disorders. Thus, the development of new strategies that can effectively prevent alcohol use disorders (AUDs) is of paramount importance. Currently approved medications attempt to deter alcohol intake by blocking ethanol metabolism or by targeting the neurochemical systems downstream of the cascades leading to craving and dependence. Unfortunately, these medications have provided only limited success as indicated by the continued high rates of alcohol abuse and alcoholism. The lack of currently available effective treatment strategies is highlighted by the urgent call by the NIAAA to find new and paradigm-changing therapeutics to either prevent or treat alcohol-related problems. This mini-review highlights recent findings from 4 laboratories with a focus on compounds that have the potential to be novel therapeutic agents that can be developed for the prevention and/or treatment of AUDs.

KW - Dihydromyricetin

KW - GABA receptors

KW - Ganaxolone

KW - Glial cell line-derived neurotrophic factor

KW - Ivermectin

KW - Purinergic receptors

UR - http://www.scopus.com/inward/record.url?scp=84871943577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871943577&partnerID=8YFLogxK

U2 - 10.1111/j.1530-0277.2012.01846.x

DO - 10.1111/j.1530-0277.2012.01846.x

M3 - Article

C2 - 22671690

AN - SCOPUS:84871943577

VL - 37

SP - 8

EP - 15

JO - Alcoholism: Clinical and Experimental Research

JF - Alcoholism: Clinical and Experimental Research

SN - 0145-6008

IS - 1

ER -